Riccardo Lencioni, MD, discusses how the new protocol from the phase 3 EMERALD-1 trial may be implemented in the community oncology setting for the treatment of hepatocellular carcinoma.
Riccardo Lencioni, MD, professor in the department of radiology at the University of Pisa School of Medicine in Pisa, Italy, discusses how the new protocol from the phase 3 EMERALD-1 trial (NCT03778957) of durvalumab (Imfinzi), transarterial chemoembolization (TACE), and bevacizumab (Avastin) may be implemented in the community oncology setting for the treatment of hepatocellular carcinoma (HCC).
The randomized, double-blind, placebo-controlled, multicenter phase 3 EMERALD-1 trial is investigating a combined treatment approach for patients with unresectable hepatocellular carcinoma (HCC) who are eligible for TACE, a a minimally invasive, targeted procedure that aims to block the blood supply to the tumor and deliver chemotherapy directly to it.1 Patients in the study were randomly assigned to 1 of 3 groups. Enrollment in the phase 3 trial was open to patients who had confirmed HCC not amenable to curative therapy, a Child-Pugh score class A to B7, and an ECOG performance status of 0 or 1.
The primary end point of the study is progression-free survival (PFS) in arm A vs arm C by blinded independent radiology review using RECIST v1.1, and secondary end points include PFS for arm B vs arm C, overall survival, health-related quality-of-life measures, and safety. Lencioni presented updated findings from the study at the 2024 Gastrointestinal Cancers Symposium.
Transcription:
0:09 | The treatment regimen included 2 different parts. The first part is represented by TACE, which is combined with durvalumab. Then at and upon completion of the TACE cycles, patients were started on the combination of durvalumab and atezolizumab.
Gholam Analyzes Treatment Outcomes for Advanced HCC in Child-Pugh B Population
April 28th 2024During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More